default author photo

James Barnes

University of Melbourne - WHO Collaborating Centre for Reference and Research on Influenza

SCHOLARLY PAPERS

2

DOWNLOADS

102

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

Long-Term Safety and Immunogenicity of an MF59-Adjuvanted Spike Glycoprotein-Clamp Vaccine for SARS-CoV-2 in Adults Aged 18–55 Years or ≥56 Years: 12-Month Results from a Randomised, Double-Blind, Placebo-Controlled, Phase 1 Trial

Number of pages: 51 Posted: 28 Mar 2023
University of Queensland - School of Chemistry and Molecular Biosciences, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Queensland - School of Chemistry and Molecular Biosciences, University of Queensland - School of Chemistry and Molecular Biosciences, University of Melbourne, Australian National University (ANU) - Department of Immunology and Infectious Disease, University of Queensland - School of Chemistry and Molecular Biosciences, University of Queensland - School of Chemistry and Molecular Biosciences, University of Queensland - School of Medicine, Tanawell Consulting, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), Agilex Biolabs, Agilex Biolabs, University of Melbourne - WHO Collaborating Centre for Reference and Research on Influenza, University of Melbourne - WHO Collaborating Centre for Reference and Research on Influenza, University of Melbourne - Department of Microbiology and Immunology (DMI), Australian National University (ANU) - Department of Immunology and Infectious Disease, University of Melbourne - WHO Collaborating Centre for Reference and Research on Influenza, University of Queensland - Institute for Molecular Bioscience, University of Queensland - School of Chemistry and Molecular Biosciences and University of Queensland - School of Chemistry and Molecular Biosciences
Downloads 78 (816,709)

Abstract:

Loading...

Clinical trial, phase 1, COVID-19 vaccine, Severe acute respiratory syndrome coronavirus 2, Spike protein, SARS-CoV-2, Molecular clamp

2.

Antigenic Effects of Influenza A(H3n2) Virus Egg-Adaptation Substitutions are Influenced by Evolution Associated Substitutions

Number of pages: 25 Posted: 28 Aug 2023
University of Melbourne - WHO Collaborating Centre for Reference and Research on Influenza, University of Melbourne - WHO Collaborating Centre for Reference and Research on Influenza, University of Melbourne - WHO Collaborating Centre for Reference and Research on Influenza, University of Melbourne - WHO Collaborating Centre for Reference and Research on Influenza, University of Melbourne - WHO Collaborating Centre for Reference and Research on Influenza, University of Melbourne - WHO Collaborating Centre for Reference and Research on Influenza, University of Melbourne - WHO Collaborating Centre for Reference and Research on Influenza, University of Melbourne - WHO Collaborating Centre for Reference and Research on Influenza, University of Melbourne - WHO Collaborating Centre for Reference and Research on Influenza and University of Melbourne - WHO Collaborating Centre for Reference and Research on Influenza
Downloads 24 (1,399,036)

Abstract:

Loading...

influenza virus, vaccine, antibodies, A(H3N2), antigenic change, genetic change, evolution